RESUMEN
There is increasing interest in how immune cells in the meninges-the membranes that surround the brain and spinal cord-contribute to homeostasis and disease in the central nervous system1,2. The outer layer of the meninges, the dura mater, has recently been described to contain both innate and adaptive immune cells, and functions as a site for B cell development3-6. Here we identify organized lymphoid structures that protect fenestrated vasculature in the dura mater. The most elaborate of these dural-associated lymphoid tissues (DALT) surrounded the rostral-rhinal confluence of the sinuses and included lymphatic vessels. We termed this structure, which interfaces with the skull bone marrow and a comparable venous plexus at the skull base, the rostral-rhinal venolymphatic hub. Immune aggregates were present in DALT during homeostasis and expanded with age or after challenge with systemic or nasal antigens. DALT contain germinal centre B cells and support the generation of somatically mutated, antibody-producing cells in response to a nasal pathogen challenge. Inhibition of lymphocyte entry into the rostral-rhinal hub at the time of nasal viral challenge abrogated the generation of germinal centre B cells and class-switched plasma cells, as did perturbation of B-T cell interactions. These data demonstrate a lymphoid structure around vasculature in the dura mater that can sample antigens and rapidly support humoral immune responses after local pathogen challenge.
Asunto(s)
Duramadre , Inmunidad Humoral , Tejido Linfoide , Venas , Administración Intranasal , Antígenos/administración & dosificación , Antígenos/inmunología , Médula Ósea/inmunología , Sistema Nervioso Central/irrigación sanguínea , Sistema Nervioso Central/inmunología , Duramadre/irrigación sanguínea , Duramadre/inmunología , Centro Germinal/citología , Centro Germinal/inmunología , Vasos Linfáticos/inmunología , Tejido Linfoide/irrigación sanguínea , Tejido Linfoide/inmunología , Células Plasmáticas/inmunología , Cráneo/irrigación sanguínea , Linfocitos T/inmunología , Venas/fisiología , Humanos , Masculino , Femenino , Adulto , Persona de Mediana Edad , Animales , Ratones , Anciano de 80 o más AñosRESUMEN
Post-transcriptional regulation of mRNA by the RNA-binding protein HuR (encoded by Elavl1) is required in B cells for the germinal center reaction and for the production of class-switched antibodies in response to thymus-independent antigens. Transcriptome-wide examination of RNA isoforms and their abundance and translation in HuR-deficient B cells, together with direct measurements of HuR-RNA interactions, revealed that HuR-dependent splicing of mRNA affected hundreds of transcripts, including that encoding dihydrolipoamide S-succinyltransferase (Dlst), a subunit of the 2-oxoglutarate dehydrogenase (α-KGDH) complex. In the absence of HuR, defective mitochondrial metabolism resulted in large amounts of reactive oxygen species and B cell death. Our study shows how post-transcriptional processes control the balance of energy metabolism required for the proliferation and differentiation of B cells.
Asunto(s)
Linfocitos B/inmunología , Proteínas ELAV/inmunología , Centro Germinal/inmunología , Inmunidad Humoral , Inmunoglobulinas/biosíntesis , ARN Mensajero/inmunología , Aciltransferasas/genética , Aciltransferasas/inmunología , Empalme Alternativo/inmunología , Animales , Antígenos/administración & dosificación , Antígenos/inmunología , Linfocitos B/citología , Linfocitos B/efectos de los fármacos , Muerte Celular , Diferenciación Celular , Proliferación Celular , Proteínas ELAV/genética , Eritrocitos/inmunología , Centro Germinal/citología , Centro Germinal/efectos de los fármacos , Inmunización , Cambio de Clase de Inmunoglobulina , Lipopolisacáridos/farmacología , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Mitocondrias/genética , Mitocondrias/inmunología , ARN Mensajero/genética , Especies Reactivas de Oxígeno/inmunología , Especies Reactivas de Oxígeno/metabolismo , OvinosRESUMEN
Interleukin (IL)-2 is a pleiotropic cytokine that is necessary to prevent chronic inflammation in the gastrointestinal tract1-4. The protective effects of IL-2 involve the generation, maintenance and function of regulatory T (Treg) cells4-8, and the use of low doses of IL-2 has emerged as a potential therapeutic strategy for patients with inflammatory bowel disease9. However, the cellular and molecular pathways that control the production of IL-2 in the context of intestinal health are undefined. Here we show, in a mouse model, that IL-2 is acutely required to maintain Treg cells and immunological homeostasis throughout the gastrointestinal tract. Notably, lineage-specific deletion of IL-2 in T cells did not reduce Treg cells in the small intestine. Unbiased analyses revealed that, in the small intestine, group-3 innate lymphoid cells (ILC3s) are the dominant cellular source of IL-2, which is induced selectively by IL-1ß. Macrophages in the small intestine produce IL-1ß, and activation of this pathway involves MYD88- and NOD2-dependent sensing of the microbiota. Our loss-of-function studies show that ILC3-derived IL-2 is essential for maintaining Treg cells, immunological homeostasis and oral tolerance to dietary antigens in the small intestine. Furthermore, production of IL-2 by ILC3s was significantly reduced in the small intestine of patients with Crohn's disease, and this correlated with lower frequencies of Treg cells. Our results reveal a previously unappreciated pathway in which a microbiota- and IL-1ß-dependent axis promotes the production of IL-2 by ILC3s to orchestrate immune regulation in the intestine.
Asunto(s)
Inmunidad Innata/inmunología , Interleucina-2/inmunología , Intestinos/citología , Intestinos/inmunología , Linfocitos T Reguladores/inmunología , Animales , Antígenos/administración & dosificación , Antígenos/inmunología , Enfermedad de Crohn/inmunología , Enfermedad de Crohn/metabolismo , Enfermedad de Crohn/patología , Femenino , Microbioma Gastrointestinal/inmunología , Homeostasis/inmunología , Humanos , Inflamación/inmunología , Inflamación/patología , Interleucina-1beta/inmunología , Interleucina-1beta/metabolismo , Interleucina-2/deficiencia , Interleucina-2/metabolismo , Intestino Delgado/citología , Intestino Delgado/inmunología , Macrófagos/inmunología , Macrófagos/metabolismo , Masculino , Ratones , Factor 88 de Diferenciación Mieloide/deficiencia , Factor 88 de Diferenciación Mieloide/genética , Factor 88 de Diferenciación Mieloide/metabolismo , Proteína Adaptadora de Señalización NOD2/deficiencia , Proteína Adaptadora de Señalización NOD2/genética , Proteína Adaptadora de Señalización NOD2/metabolismo , Linfocitos T Reguladores/clasificación , Linfocitos T Reguladores/metabolismoRESUMEN
Herein, we report a transdermal patch prepared using an ionic liquid-based solid in oil (IL-S/O) nanodispersion and a pressure-sensitive adhesive (PSA) to deliver the macromolecular antigenic protein, ovalbumin (OVA). The IL-S/O nanodispersion and a PSA were first mixed at an equal weight ratio, then coated onto a release liner, and covered with a support film. To evaluate the effect of the PSA, three types of PSAs, DURO-TAK 87-4098, DURO-TAK 87-4287, and DURO-TAK 87-235A, were used to obtain the corresponding IL-S/O patches SP-4098, SP-4287, and SP-235A, respectively. The prepared IL-S/O patches were characterized for surface morphology, viscoelasticity, and moisture content. In vitro skin penetration and in vivo immunization studies of the IL-S/O patches were performed using Yucatan micropig skin and the C57BL/6NJc1 mice model, respectively. The SP-4098 and SP-4287 delivered 5.49-fold and 5.47-fold higher amounts of drug compared with the aqueous formulation. Although both patches delivered a similar amount of drug, SP-4287 was not detached fully from the release liner after 30 days, indicating low stability. Mice immunized with the OVA-containing SP-4098 produced a 10-fold increase in anti-OVA IgG compared with those treated with an aqueous formulation. These findings suggested that the IL-S/O patch may be a good platform for the transdermal delivery of antigen molecules.
Asunto(s)
Administración Cutánea , Antígenos , Inmunización , Líquidos Iónicos , Ovalbúmina , Parche Transdérmico , Líquidos Iónicos/química , Animales , Ratones , Ovalbúmina/inmunología , Ovalbúmina/administración & dosificación , Antígenos/inmunología , Antígenos/administración & dosificación , Antígenos/química , Porcinos , Piel/metabolismo , Piel/inmunología , Sistemas de Liberación de Medicamentos , Ratones Endogámicos C57BL , Femenino , Absorción CutáneaRESUMEN
Food allergy is an antigen-specific immunological adverse reaction after exposure to a given food. Multiple clinical studies showed that oral immunotherapy (OIT) is effective for the prevention and treatment for food allergy that is developed in infants and children. However, the effectiveness of OIT for epicutaneously sensitized food allergy remains unclear. Previously, we established a mouse model of epicutaneous-sensitized food allergy. In this model, systemic allergic reaction including intestinal and skin symptoms, such as anaphylaxis, was observed. We treated this model with OIT in two ways (OIT before sensitization or OIT during the sensitization phase) and evaluated the preventive effect of both methods. OIT before sensitization significantly ameliorated mast cell degranulation in sensitized skin, but there was no decrease in rectal temperatures or in mast cell degranulation in the jejunum. However, OIT administered during the sensitization phase significantly ameliorated the decrease in rectal temperature and mast cell degranulation in the skin and jejunum. OIT before sensitization increased the regulatory T cells in mesenteric lymph node (MLN), but not in the spleen, and it reduced antigen-specific IgG, but not IgE, production compared with the non-OIT control. However, OIT during sensitization caused a greater increase in regulatory T cells in both the MLN and spleen and reduced antigen-specific IgE and IgG generation compared with the non-OIT control group. Thus, OIT during the sensitization phase was effective for the prevention of epicutaneous-sensitized food allergy.
Asunto(s)
Anafilaxia/prevención & control , Desensibilización Inmunológica/métodos , Hipersensibilidad a los Alimentos/prevención & control , Tolerancia Inmunológica , Enfermedades de la Piel/inmunología , Piel/inmunología , Administración Cutánea , Administración Oral , Anafilaxia/inmunología , Animales , Antígenos/administración & dosificación , Antígenos/inmunología , Temperatura Corporal , Degranulación de la Célula , Quimasas/sangre , Modelos Animales de Enfermedad , Hipersensibilidad a los Alimentos/sangre , Hipersensibilidad a los Alimentos/complicaciones , Hipersensibilidad a los Alimentos/inmunología , Inmunoglobulina E/sangre , Inmunoglobulina G/sangre , Yeyuno/inmunología , Ganglios Linfáticos/patología , Mastocitos/inmunología , Mesenterio , Ratones , Ovalbúmina/administración & dosificación , Ovalbúmina/inmunología , Bazo/patología , Linfocitos T Reguladores/patologíaRESUMEN
Despite the many advances that have occurred in the field of vaccine adjuvants, there are still unmet needs that may enable the development of vaccines suitable for more challenging pathogens (e.g., HIV and tuberculosis) and for cancer vaccines. Liposomes have already been shown to be highly effective as adjuvant/delivery systems due to their versatility and likely will find further uses in this space. The broad potential of lipid-based delivery systems is highlighted by the recent approval of COVID-19 vaccines comprising lipid nanoparticles with encapsulated mRNA. This review provides an overview of the different approaches that can be evaluated for the design of lipid-based vaccine adjuvant/delivery systems for protein, carbohydrate, and nucleic acid-based antigens and how these strategies might be combined to develop multicomponent vaccines.
Asunto(s)
Adyuvantes Inmunológicos/administración & dosificación , Antígenos/administración & dosificación , Sistemas de Liberación de Medicamentos , Lípidos/química , Nanopartículas/química , Vacunas/administración & dosificación , Vacunas contra la COVID-19/administración & dosificación , Humanos , Liposomas , SARS-CoV-2/inmunología , Vacunas/químicaRESUMEN
The cytokine IL-33 is a well-established inducer of Th2 responses. However, roles for IL-33 in promoting CD8, Th1, and T regulatory cell responses have also emerged. In this study, the role of IL-33 as a regulator of particulate vaccine adjuvant-induced Ag-specific cellular immunity was investigated. We found that polymeric nanoparticles surpassed alum in their ability to enhance Ag-specific CD8 and Th1 responses. IL-33 was a potent negative regulator of both CD8+ T cell and Th1 responses following i.m. vaccination with Ag and nanoparticles, whereas the cytokine was required for the nanoparticle enhancement in Ag-specific IL-10. In contrast to the effect on cellular immunity, Ab responses were comparable between vaccinated wild-type and IL-33-deficient mice. IL-33 did not compromise alum-induced adaptive cellular immunity after i.m. vaccination. These data suggest that IL-33 attenuates the induction of cellular immune responses by nanoparticulate adjuvants and should be considered in the rational design of vaccines targeting enhanced CD8 and Th1 responses.
Asunto(s)
Antígenos/inmunología , Inmunidad Celular/inmunología , Interleucina-33/inmunología , Vacunas/inmunología , Animales , Antígenos/administración & dosificación , Inyecciones Intramusculares , Interleucina-33/deficiencia , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Nanopartículas/administración & dosificación , Nanopartículas/química , Vacunación , Vacunas/administración & dosificaciónRESUMEN
BACKGROUND: Effector functions of IgG Abs are regulated by their Fc N-glycosylation pattern. IgG Fc glycans that lack galactose and terminal sialic acid residues correlate with the severity of inflammatory (auto)immune disorders and have also been linked to protection against viral infection and discussed in the context of vaccine-induced protection. In contrast, sialylated IgG Abs have shown immunosuppressive effects. OBJECTIVE: We sought to investigate IgG glycosylation programming during the germinal center (GC) reaction following immunization of mice with a foreign protein antigen and different adjuvants. METHODS: Mice were analyzed for GC T-cell, B-cell, and plasma cell responses, as well as for antigen-specific serum IgG subclass titers and Fc glycosylation patterns. RESULTS: Different adjuvants induce distinct IgG+ GC B-cell responses with specific transcriptomes and expression levels of the α2,6-sialyltransferase responsible for IgG sialylation that correspond to distinct serum IgG Fc glycosylation patterns. Low IgG Fc sialylation programming in GC B cells was overall highly dependent on the Foxp3- follicular helper T (TFH) cell-inducing cytokine IL-6, here in particular induced by water-in-oil adjuvants and Mycobacterium tuberculosis. Furthermore, low IgG Fc sialylation programming was dependent on adjuvants that induced IL-27 receptor-dependent IFN-γ+ TFH1 cells, IL-6/IL-23-dependent IL-17A+ TFH17 cells, and high ratios of TFH cells to Foxp3+ follicular regulatory T cells. Here, the 2 latter were dependent on M tuberculosis and its cord factor. CONCLUSION: This study's findings regarding adjuvant-dependent GC responses and IgG glycosylation programming may aid in the development of novel vaccination strategies to induce IgG Abs with both high affinity and defined Fc glycosylation patterns in the GC.
Asunto(s)
Adyuvantes Inmunológicos/administración & dosificación , Antígenos/administración & dosificación , Centro Germinal/inmunología , Inmunoglobulina G/inmunología , Compuestos de Alumbre/administración & dosificación , Animales , Linfocitos B/efectos de los fármacos , Linfocitos B/inmunología , Citocinas/inmunología , Femenino , Adyuvante de Freund/administración & dosificación , Glicosilación , Lipopolisacáridos/administración & dosificación , Ratones Endogámicos C57BL , Ratones Noqueados , Aceite Mineral/administración & dosificación , Mycobacterium tuberculosis/inmunología , Ovalbúmina/administración & dosificación , Polisorbatos/administración & dosificación , Escualeno/administración & dosificación , Linfocitos T/efectos de los fármacos , Linfocitos T/inmunología , VacunaciónRESUMEN
A major obstacle to tuberculosis (TB)-subunit-vaccine development has been the induction of inadequate levels of protective immunity due to the limited breadth of antigen in vaccine preparations. In this study, immunogenic mycobacterial fusion peptides Ag85B-TB10.4 and Ag85B-TB10.4-Rv2660c were covalently displayed on the surface of self-assembled polyester particles. This study investigated whether polyester particles displaying mycobacterial antigens could provide augmented immunogenicity (i.e., offer an innovative vaccine formulation) when compared with free soluble antigens. Herein, polyester particle-based particulate vaccines were produced in an endotoxin-free Escherichia coli strain and emulsified with the adjuvant dimethyl dioctadecyl ammonium bromide. C57BL/6 mice were used to study the immunogenicity of formulated particulate vaccines. The result of humoral immunity showed the antibodies only interacted with target antigens and not with PhaC and the background proteins of the production host. The analysis of T helper 1 cellular immunity indicated that a relatively strong production of cellular immunity biomarkers, IFN-γ and IL-17A cytokines, was induced by particulate vaccines when compared with the respective soluble controls. This study demonstrated that polyester particles have the potential to perform as a mycobacterial antigen-delivery agent to induce augmented antigen-specific immune responses in contrast to free soluble vaccines.-Chen, S., Sandford, S., Kirman, J. R., Rehm, B. H. A. Innovative antigen carrier system for the development of tuberculosis vaccines.
Asunto(s)
Antígenos/administración & dosificación , Portadores de Fármacos , Vacunas contra la Tuberculosis/administración & dosificación , Animales , Medios de Cultivo , Citocinas/metabolismo , Escherichia coli/genética , Humanos , Ratones , Ratones Endogámicos C57BL , Mycobacterium tuberculosis/inmunologíaRESUMEN
Background: Recent advancements in therapeutic strategies have attracted considerable attention to control the acute organs and tissues rejection, which is the main cause of mortality in transplant recipients. The long-term usage of immunosuppressive drugs compromises the body immunity against simple infections and decrease the patients' quality of life. Tolerance of allograft in recipients without harming the rest of host immune system is the basic idea to develop the therapeutic approaches after induction of donor-specific transplant. Methods: Controlled and targeted delivery system by using biomimetic micro and nanoparticles as carriers is an effective strategy to deplete the immune cells in response to allograft in an antigen-specific manner. Polylactic-co-glycolic acid (PLGA) is a biocompatible and biodegradable polymer, which has frequently being used as drug delivery vehicle. Results: This review focuses on the biomedical applications of PLGA based biomimetic micro and nano-sized particles in drug delivery systems to prolong the survival of alloskin graft. Conclusion: We will discuss the mediating factors for rejection of alloskin graft, selective depletion of immune cells, controlled release mechanism, physiochemical properties, size-based body distribution of PLGA particles and their effect on overall host immune system.
Asunto(s)
Portadores de Fármacos , Diseño de Fármacos , Rechazo de Injerto/prevención & control , Factores Inmunológicos/administración & dosificación , Inmunosupresores/administración & dosificación , Copolímero de Ácido Poliláctico-Ácido Poliglicólico , Trasplante de Piel/efectos adversos , Aloinjertos , Animales , Antígenos/administración & dosificación , Antígenos/inmunología , Biomimética/métodos , Fenómenos Químicos , Preparaciones de Acción Retardada , Portadores de Fármacos/química , Sistemas de Liberación de Medicamentos , Desarrollo de Medicamentos , Liberación de Fármacos , Rechazo de Injerto/tratamiento farmacológico , Rechazo de Injerto/inmunología , Supervivencia de Injerto/efectos de los fármacos , Supervivencia de Injerto/inmunología , Humanos , Inmunomodulación/efectos de los fármacos , Nanopartículas/química , Copolímero de Ácido Poliláctico-Ácido Poliglicólico/química , Trasplante de Piel/métodos , Trasplante HomólogoRESUMEN
Mucosal delivery of antigens can induce both humoral and cellular immune responses. Particularly, the nasal cavity is a strongly inductive site for mucosal immunity among several administration routes, as it is generally the first point of contact for inhaled antigens. However, the delivery of antigens to the nasal cavity has some disadvantages such as rapid clearance and disposition of inhaled materials. For these reasons, remarkable efforts have been made to develop antigen delivery systems which suit the nasal route. The use of nanoparticles as delivery vehicles enables protection of the antigen from degradation and sustains the release of the loaded antigen, eventually resulting in improved vaccine and/or drug efficacy. Chitosan, which exhibits low toxicity, biodegradability, good cost performance, and strong mucoadhesive properties, is a useful material for nanoparticles. The present review provides an overview of the mucosal immune response induced by nanoparticles, recent advances in the use of nanoparticles, and nasal delivery systems with chitosan nanoparticles.
Asunto(s)
Antígenos/administración & dosificación , Quitosano/química , Portadores de Fármacos , Nanopartículas , Vacunas/administración & dosificación , Adhesividad , Administración Intranasal , Animales , Antígenos/química , Preparaciones de Acción Retardada , Composición de Medicamentos , Estabilidad de Medicamentos , Humanos , Inmunidad Mucosa/efectos de los fármacos , Nanomedicina , Mucosa Nasal/efectos de los fármacos , Mucosa Nasal/inmunología , Mucosa Nasal/metabolismo , Vacunas/químicaRESUMEN
Self-assembling protein nanoparticles are extensively and increasingly engineered to integrate adjuvants with antigens to elicit potent and long-term immunity due to uniform architecture, inherent biocompatibility, and excellent plasticity. However, functionalization of nanoparticles by surface tailoring has two common problems: (1) disassembly caused by loaded cargoes; and (2) an adjuvant that is inconvenient to co-deliver with an antigen by genetic fusion. Here, we report an intein-mediated trans-splicing approach that overcomes the detrimental effects of loaded proteins on ferritin nanoparticle stability and allows concurrent display of antigen and adjuvant in a facile, efficient, and site-specific manner. An immunization study with an epitope-based model antigen reveals that antigen and adjuvant co-delivery nanoparticles induce a more potent protective immunity than other formulations do. Our results demonstrate that protein engineering represents an intriguing approach for antigen/adjuvant co-delivery to potentiate antigen-associated immune responses.
Asunto(s)
Adyuvantes Inmunológicos/administración & dosificación , Antígenos/administración & dosificación , Portadores de Fármacos/química , Ferritinas/química , Inteínas , Nanopartículas/química , Animales , Ratones Endogámicos ICR , Modelos Moleculares , Trans-EmpalmeRESUMEN
Lymph node follicles capture and retain antigens to induce germinal centers and long-lived humoral immunity. However, control over antigen retention has been limited. Here we discovered that antigen conjugated to nanoparticle carriers of different sizes impacts the intralymph node transport and specific cell interaction. We found that follicular dendritic cell (FDC) networks determine the intralymph node follicle fate of these nanoparticles by clearing smaller ones (5-15 nm) within 48 h and retaining larger ones (50-100 nm) for over 5 weeks. The 50-100 nm-sized nanoparticles had 175-fold more delivery of antigen at the FDC dendrites, 5-fold enhanced humoral immune responses of germinal center B cell formation, and 5-fold more antigen-specific antibody production over 5-15 nm nanoparticles. Our results show that we can tune humoral immunity by simply manipulating the carrier size design to produce effectiveness of vaccines.
Asunto(s)
Antígenos/inmunología , Inmunidad Humoral , Ganglios Linfáticos/inmunología , Nanoconjugados/química , Ovalbúmina/inmunología , Animales , Antígenos/administración & dosificación , Linfocitos B/inmunología , Células Dendríticas/inmunología , Centro Germinal/inmunología , Oro/química , Proteínas Inmovilizadas/inmunología , Ratones , Ratones Endogámicos C57BL , Ovalbúmina/administración & dosificación , Tamaño de la Partícula , Vacunas/administración & dosificación , Vacunas/inmunologíaRESUMEN
Vaccination represents one of the most effective means of preventing infectious disease. In order to maximize the utility of vaccines, highly potent formulations that are easy to administer and promote high patient compliance are desired. In the present work, a biomimetic self-propelling micromotor formulation is developed for use as an oral antivirulence vaccine. The propulsion is provided by a magnesium-based core, and a biomimetic cell membrane coating is used to detain and neutralize a toxic antigenic payload. The resulting motor toxoids leverage their propulsion properties in order to more effectively elicit mucosal immune responses. After demonstrating the successful fabrication of the motor toxoids, their uptake properties are shown in vitro. When delivered to mice via an oral route, it is then confirmed that the propulsion greatly improves retention and uptake of the antigenic material in the small intestine in vivo. Ultimately, this translates into markedly elevated generation of antibody titers against a model toxin. This work provides a proof-of-concept highlighting the benefits of active oral delivery for vaccine development, opening the door for a new set of applications, in which biomimetic motor technology can provide significant benefits.
Asunto(s)
Antígenos/administración & dosificación , Antivirales/administración & dosificación , Biomimética , Enfermedades Transmisibles/terapia , Administración Oral , Animales , Antígenos/inmunología , Antivirales/inmunología , Enfermedades Transmisibles/inmunología , Enfermedades Transmisibles/patología , Humanos , Inmunidad Mucosa/efectos de los fármacos , Magnesio/química , Ratones , Toxoides/metabolismo , Toxoides/toxicidad , Vacunación/métodosRESUMEN
The skin is an attractive site for vaccination and harbors a dense network of Langerhans cells that are the prime target for antigen delivery approaches in the epidermis. While specific targeting of Langerhans cells has been shown to elicit the necessary T-cell response using antibody-based delivery approaches, the targeted administration of particulate antigens in the form of nanoparticle-based vaccine formulations has been challenging. We previously reported on a specific targeting ligand for human Langerin, a C-type lectin expressed on Langerhans cells. This ligand is presented on liposomes and renders them highly specific for the uptake by Langerhans cells. Here we show a detailed study of the uptake and intracellular routing of the particles in model cell lines by confocal and live cell imaging as well as flow cytometric assays. Liposomes are internalized into early endosomal compartments and accumulate in late endosomes and lysosomes, shortly followed by a release of the cargo. Furthermore, we show the encapsulation of protein antigens and their delivery to cell lines and primary human Langerhans cells. These data further support the applicability of the targeted liposomal particles for protein vaccine applications.
Asunto(s)
Antígenos CD/inmunología , Antígenos/inmunología , Sistemas de Liberación de Medicamentos/métodos , Células de Langerhans/metabolismo , Lectinas Tipo C/inmunología , Liposomas , Lectinas de Unión a Manosa/inmunología , Anticuerpos/inmunología , Presentación de Antígeno/inmunología , Antígenos/administración & dosificación , Endosomas/metabolismo , Células Epidérmicas/inmunología , Células Epidérmicas/metabolismo , Células HEK293 , Humanos , Concentración de Iones de Hidrógeno , Células de Langerhans/inmunología , Activación de Linfocitos , Albúmina Sérica Bovina/administración & dosificación , Albúmina Sérica Bovina/inmunología , Piel/metabolismo , Linfocitos T/inmunología , Vacunación/métodos , Vacunas/inmunologíaRESUMEN
Cancer immunotherapy that induces a tumor-specific immune response for cancer eradication has received tremendous attention. To enhance the immunotherapeutic effects, many drug delivery strategies have been developed to overcome the physiological barriers as well as to reduce toxicity. For example, intratumoral or peritumoral administration of injectable depot formulations can directly target tumor sites for immunotherapy. Compared with systemic administration of therapeutics, this strategy has minimal side effects. Such local treatment can also trigger a systemic immune response for inhibiting tumor metastasis. This Topical Review highlights the recent studies on depot-mediated delivery of protein/peptide therapeutics for cancer immunotherapy. Further opportunities and challenges in this field are also discussed.
Asunto(s)
Inmunoterapia/métodos , Neoplasias/terapia , Proteínas/administración & dosificación , Animales , Anticuerpos/administración & dosificación , Anticuerpos/uso terapéutico , Antígenos/administración & dosificación , Antígenos/uso terapéutico , Vacunas contra el Cáncer/administración & dosificación , Vacunas contra el Cáncer/uso terapéutico , Citocinas/administración & dosificación , Citocinas/uso terapéutico , Humanos , Proteínas/uso terapéuticoRESUMEN
Induction of cancer-specific cytotoxic T lymphocytes is crucially important to complement therapeutic effects of immune checkpoint inhibitors and to achieve efficient cancer immunotherapy. To induce cancer-specific cytotoxic T lymphocytes, cancer antigen carriers must have multiple functions to deliver cancer antigens to antigen presenting cells, release antigens into cytosol, and promote the maturation of these cells. We earlier achieved cytosolic delivery of antigens and induction of antigen-specific cytotoxic T lymphocytes using carboxylated polyglycidol or polysaccharide derivative-modified liposomes that can induce membrane fusion with endosomes in response to weakly acidic pH. Furthermore, pH-sensitivity and adjuvant properties of these polymers were enhanced strongly by introduction of hydrophobic carboxylated units to dextran. Against our expectations, these polymer-modified liposomes only slightly induce cancer immunity, probably because of the high hydrophobicity of spacer units. This study used a polysaccharide with charged groups (chondroitin sulfate) instead of dextran as a backbone to reduce hydrophobicity. Chondroitin sulfate derivative-modified liposomes showed almost equal pH-sensitivity to that of dextran derivative-modified liposomes and achieved selective delivery to dendritic cells, whereas dextran derivative-modified liposomes were highly taken up by both dendritic cells and fibroblasts. Chondroitin sulfate derivative-modified liposomes delivered model antigenic proteins into cytosol of dendritic cells and promoted cytokine production from the cells, leading to tumor regression on tumor-bearing mice after subcutaneous administration. Results demonstrate that charged groups having polysaccharide as a backbone can be used in an effective strategy to balance strong hydrophobicity of spacer units with their utilization for immunity-inducing systems.
Asunto(s)
Antígenos/administración & dosificación , Sulfatos de Condroitina/química , Concentración de Iones de Hidrógeno , Liposomas , Neoplasias/inmunología , Polímeros/química , Animales , Interacciones Hidrofóbicas e Hidrofílicas , RatonesRESUMEN
T-cell receptor (TCR)-transgenic mice have been employed for evaluating antigen-response mechanisms, but their non-endogenous TCR might induce immune response differently than the physiologically expressed TCR Nuclear transfer cloning produces animals that retain the donor genotype in all tissues including germline and immune systems. Taking advantage of this feature, we generated cloned mice that carry endogenously rearranged TCR genes from antigen-specific CD4+ T cells. We show that T cells of the cloned mice display distinct developmental pattern and antigen reactivity because of their endogenously pre-rearranged TCRα (rTα) and TCRß (rTß) alleles. These alleles were transmitted to the offspring, allowing us to establish a set of mouse lines that show chronic-type allergic phenotypes, that is, bronchial and nasal inflammation, upon local administrations of the corresponding antigens. Intriguingly, the existence of either rTα or rTß is sufficient to induce in vivo hypersensitivity. These cloned mice expressing intrinsic promoter-regulated antigen-specific TCR are a unique animal model with allergic predisposition for investigating CD4+ T-cell-mediated pathogenesis and cellular commitment in immune diseases.
Asunto(s)
Linfocitos T CD4-Positivos/inmunología , Hipersensibilidad/inmunología , Técnicas de Transferencia Nuclear , Receptores de Antígenos de Linfocitos T/genética , Alelos , Animales , Antígenos/administración & dosificación , Antígenos/inmunología , Clonación de Organismos , Modelos Animales de Enfermedad , Ratones , Ratones Transgénicos , Receptores de Antígenos de Linfocitos T/inmunologíaRESUMEN
The oomycetous pathogen Pythium insidiosum is the causative agent of pythiosis, a life-threatening disease that affects animals and humans. This infectious disease is difficult to treat, and early and accurate diagnosis is critical for effective treatment. In this sense, this study aimed to evaluate the intradermal (ID) injection of P. insidiosum protein antigens (PiPA) for the diagnosis and treatment of pythiosis using an experimental model. For diagnostic purposes, PiPA were injected by the ID route in the following groups of rabbits: (a) control; (b) previously immunized with PiPA injected by the subcutaneous (SC) route; and (c) infected with P. insidiosum zoospores. For treatment purposes, rabbits with pythiosis were also treated with PiPA by the ID or SC routes. Mean induration sizes were different at 24 h and 72 h readings when compared to the control group. Sensitivity of the protocol was 100% at 24 h and 80% at 72 h, with 100% specificity in both readings. PiPA treatment using ID or SC routes did not result in significant differences in lesion sizes and cure rates; however, serum levels of interferon-gamma were higher in SC route. This study demonstrates the applicability of PiPA ID for diagnosis and treatment of pythiosis in an experimental model.
Asunto(s)
Antígenos/administración & dosificación , Pitiosis/diagnóstico , Pitiosis/terapia , Pythium/química , Animales , Antígenos/inmunología , Citocinas/sangre , Modelos Animales de Enfermedad , Inyecciones Intradérmicas , Interferón gamma/sangre , Pythium/inmunología , ConejosRESUMEN
In order to compare the effect of substituting fish meal with fermented soybean meal and soybean meal, and confirmed whether the benefit from the two feed materials was related to the content of inclusive soybean antigen protein, two experiments were designed. In experiment 1, one of the two practical diets contained 24.9% soybean meal (SBM), the other one containing 8% fermented soybean meal and 16.95% soybean meal (FSBM); in experiment 2, two semi-purified diets were included with high antigen protein (SPD1) and low antigen protein (SPD2) approximately equal to SBM and FSBM group respectively in experiment 1. Diets were fed to Litopenaeus vannamei (initial weight: 7.48⯱â¯0.24â¯g) for 60 days. The results showed that in experiment 1, growth performance was not significantly different between two groups, the enzyme activity (AKP, AST, ALT, SOD and LZM) and mRNA expression levels of TLR, LZM, IMD and HSP70 were significantly higher in the SBM group; In experiment 2, weight gain and specific growth rate were significantly higher in the SPD2 group, while higher activities of AKP, ALT and LZM, lower expression levels of TLRmRNA, LZMmRNA and IMDmRNA and higher expression level of HSP70mRNA were found in SPD1 group. These results implied SBM was more likely to induce stress reaction in shrimp than FSBM, which were closely related to the antigen protein in SBM.